Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 83

1.

Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer.

Harter P, Mahner S, Hilpert F, Runnebaum I, Ortmann O, Mustea A, Sehouli J, du Bois A, Wagner U; for the Kommission Ovar of the Arbeitsgemeinschaft Gynäkologische Onkologie.

Geburtshilfe Frauenheilkd. 2013 Mar;73(3):221-223.

PMID:
24771913
[PubMed]
Free PMC Article
2.

Survival benefit of adding Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) at the different time-points of treatment of ovarian cancer: review of evidence.

Mulier S, Claes JP, Dierieck V, Amiel JO, Pahaut JP, Marcelis L, Bastin F, Vanderbeeken D, Finet C, Cran S, Velu T.

Curr Pharm Des. 2012;18(25):3793-803. Review.

PMID:
22591422
[PubMed - indexed for MEDLINE]
3.

Survival Benefit of Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer: A Multi-institutional Case Control Study.

Le Brun JF, Campion L, Berton-Rigaud D, Lorimier G, Marchal F, Ferron G, Oger AS, Dravet F, Jaffre I, Classe JM.

Ann Surg Oncol. 2014 Oct;21(11):3621-7. doi: 10.1245/s10434-014-3693-7. Epub 2014 May 13.

PMID:
24819120
[PubMed - in process]
4.

Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results.

Chua TC, Robertson G, Liauw W, Farrell R, Yan TD, Morris DL.

J Cancer Res Clin Oncol. 2009 Dec;135(12):1637-45. doi: 10.1007/s00432-009-0667-4. Epub 2009 Aug 23. Review.

PMID:
19701772
[PubMed - indexed for MEDLINE]
5.

Hyperthermic intraperitoneal chemotherapy in ovarian cancer: rationale and clinical data.

de Bree E, Helm CW.

Expert Rev Anticancer Ther. 2012 Jul;12(7):895-911. doi: 10.1586/era.12.72. Review.

PMID:
22845405
[PubMed - indexed for MEDLINE]
6.

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves the survival of gastric cancer patients with ovarian metastasis and peritoneal dissemination.

Wu XJ, Yuan P, Li ZY, Bu ZD, Zhang LH, Wu AW, Zong XL, Li SX, Shan F, Ji X, Ren H, Ji JF.

Tumour Biol. 2013 Feb;34(1):463-9. doi: 10.1007/s13277-012-0571-4. Epub 2012 Oct 30.

PMID:
23108893
[PubMed - indexed for MEDLINE]
7.

Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer.

Ansaloni L, Agnoletti V, Amadori A, Catena F, Cavaliere D, Coccolini F, De Iaco P, Di Battista M, Framarini M, Gazzotti F, Ghermandi C, Kopf B, Saponara M, Tauceri F, Vallicelli C, Verdecchia GM, Pinna AD.

Int J Gynecol Cancer. 2012 Jun;22(5):778-85. doi: 10.1097/IGC.0b013e31824d836c.

PMID:
22572845
[PubMed - indexed for MEDLINE]
8.

Prospective randomized trial evaluating mandatory second look surgery with HIPEC and CRS vs. standard of care in patients at high risk of developing colorectal peritoneal metastases.

Ripley RT, Davis JL, Kemp CD, Steinberg SM, Toomey MA, Avital I.

Trials. 2010 May 25;11:62. doi: 10.1186/1745-6215-11-62.

PMID:
20500867
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

The role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer.

Muñoz-Casares FC, Rufián S, Rubio MJ, Díaz CJ, Díaz R, Casado A, Arjona A, Muñoz-Villanueva MC, Muntané J.

Clin Transl Oncol. 2009 Nov;11(11):753-9.

PMID:
19917539
[PubMed - indexed for MEDLINE]
10.

Hyperthermic intraperitoneal chemotherapy with mitomycin C and 5-fluorouracil in patients at high risk of peritoneal metastasis from colorectal cancer: A preliminary clinical study.

Shimizu T, Murata S, Sonoda H, Mekata E, Ohta H, Takebayashi K, Miyake T, Tani T.

Mol Clin Oncol. 2014 May;2(3):399-404. Epub 2014 Jan 16.

PMID:
24772307
[PubMed]
Free PMC Article
11.

Intraperitoneal chemotherapy from Armstrong to HIPEC: challenges and promise.

Eskander RN, Cripe J, Bristow RE.

Curr Treat Options Oncol. 2014 Mar;15(1):27-40. doi: 10.1007/s11864-013-0264-2.

PMID:
24338278
[PubMed - in process]
12.

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of recurrent high-grade uterine sarcoma with peritoneal dissemination.

Jimenez WA, Sardi A, Nieroda C, Gushchin V.

Am J Obstet Gynecol. 2014 Mar;210(3):259.e1-8. doi: 10.1016/j.ajog.2013.11.002. Epub 2013 Nov 7.

PMID:
24211479
[PubMed - indexed for MEDLINE]
13.

Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer: a case series.

Fagotti A, Petrillo M, Costantini B, Fanfani F, Gallotta V, Chiantera V, Turco LC, Bottoni C, Scambia G.

Gynecol Oncol. 2014 Feb;132(2):303-6. doi: 10.1016/j.ygyno.2013.12.028. Epub 2013 Dec 27.

PMID:
24378877
[PubMed - indexed for MEDLINE]
14.

Treatment of peritoneal carcinomatosis from colonic cancer by cytoreduction, peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC). Experience of ten years.

Vaira M, Cioppa T, D'Amico S, de Marco G, D'Alessandro M, Fiorentini G, De Simone M.

In Vivo. 2010 Jan-Feb;24(1):79-84.

PMID:
20133981
[PubMed - indexed for MEDLINE]
15.

Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy.

Chan DL, Morris DL, Rao A, Chua TC.

Cancer Manag Res. 2012;4:413-22. doi: 10.2147/CMAR.S31070. Epub 2012 Nov 23.

PMID:
23226073
[PubMed]
Free PMC Article
16.

8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.

Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H.

Ann Surg Oncol. 2008 Sep;15(9):2426-32. doi: 10.1245/s10434-008-9966-2. Epub 2008 Jun 3.

PMID:
18521686
[PubMed - indexed for MEDLINE]
17.

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients.

Bakrin N, Cotte E, Golfier F, Gilly FN, Freyer G, Helm W, Glehen O, Bereder JM.

Ann Surg Oncol. 2012 Dec;19(13):4052-8. doi: 10.1245/s10434-012-2510-4. Epub 2012 Jul 24.

PMID:
22825772
[PubMed - indexed for MEDLINE]
18.

Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer.

Di Giorgio A, Naticchioni E, Biacchi D, Sibio S, Accarpio F, Rocco M, Tarquini S, Di Seri M, Ciardi A, Montruccoli D, Sammartino P.

Cancer. 2008 Jul 15;113(2):315-25. doi: 10.1002/cncr.23553.

PMID:
18473354
[PubMed - indexed for MEDLINE]
Free Article
19.

Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival of gastric cancer with peritoneal carcinomatosis: evidence from an experimental study.

Tang L, Mei LJ, Yang XJ, Huang CQ, Zhou YF, Yonemura Y, Li Y.

J Transl Med. 2011 May 7;9:53. doi: 10.1186/1479-5876-9-53.

PMID:
21548973
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer.

Deraco M, Baratti D, Laterza B, Balestra MR, Mingrone E, Macrì A, Virzì S, Puccio F, Ravenda PS, Kusamura S.

Eur J Surg Oncol. 2011 Jan;37(1):4-9. doi: 10.1016/j.ejso.2010.11.004. Epub 2010 Nov 26. Review.

PMID:
21112721
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk